Latest News

Oslo, Norway, 15 November 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a revenue growth of 17 % to NOK 31.6 million in the third quarter of 2016 (Q3 2015: NOK 27.0) for the Hexvix/Cysview commercial franchise and a corresponding EBITDA of NOK 8.0 million.

Photocure will present its third quarter report on Tuesday 15 November 2016 at Hotel Continental, Oslo, Norway.

Oslo, Norway, October 25, 2016 Photocure ASA announced that new data on Blue Light Cystoscopy with Cysview®/Hexvix® were presented at the Société Internationale d'Urologie (SIU) Annual meeting, October 20th to 23rd, Buenos Aires, Argentina: an ePoster from a US registry study and an ePoster video on Blue Light Flexible Cystoscopy.

Oslo, Norway, September 28th, 2016: Photocure ASA announced today that a study published on-line in the peer reviewed Journal of Urology, shows that there is no significant statistical difference in the frequency or grade of adverse events in patients having one Blue Light Cystoscopy with Cysview® (BLCC) versus repeat BLCC procedures.

Edison Group, an investment intelligence firm, has published a report on Photocure.

Blue Light Cystoscopy with Cysview® featured on the Cancer Innovations program on ABC TV in New York, NY

Update on management shareholdings and exercise of employee share options in Photocure ASA ("the Company")

Oslo, Norway, August 29, 2016, Photocure ASA hosted on August 25 an educational event in New York aimed at institutional investors and analysts, which focused on the treatment of bladder cancer.

Oslo, Norway, August 24, 2016: Photocure ASA (OSE: PHO), announces that its partner and exclusive distributor, Juno Pharmaceuticals Pty Ltd, have received marketing authorization approval (MAA) for Hexvix in Australia. The market potential in the territory is estimated to be similar to the potential in the Nordics, where Photocure commercializes Hexvix with its own sales team. Hexvix is Photocure's flagship product used to aid in the diagnosis and management of bladder cancer. Under the terms of the agreement, with the MAA approval in Australia, Photocure will receive EUR 250,000 in milestone payments.

Oslo, Norway, 23 August 2016: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology, reported a sales revenue growth of 18 % to NOK 34.2 million in the second quarter of 2016 (Q2 2015: NOK 28.9 million) for the Hexvix/Cysview commercial franchise and a corresponding EBITDA of NOK 5.9 million.

Photocure will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Oslo, Norway.

New Cysview kit has an improved design providing healthcare professionals with an improved, simplified, and easy-to-use product.

Oslo, Norway, August 2, 2016 -- Photocure ASA announced today a new systematic review and meta-analysis on the impact of Blue Light Cystoscopy (BLC) with Hexvix® (Hexaminolevulinate) - versus White Light Cystoscopy (WLC) on progression in Non-Muscle Invasive Bladder Cancer (NMIBC).

Oslo, Norway, 6 July 2016: Photocure ASA will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Norway, and is proud to announce Dr. Sia Daneshmand as keynote speaker at the event. Dr. Daneshmand will provide an update on Hexvix/Cysview following the new bladder cancer guidelines from American Urological Association (AUA) and the Society of Urological Oncology (SUO), where enhanced cystoscopy including Blue Light Cystoscopy with Hexvix/ Cysview is recommended.